Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...

The following is a summary of "Quality of life in idiopathic pulmonary fibrosis in Latin American countries," published in ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...

Leerink analyst Faisal Khurshid downgraded Pliant Therapeutics (PLRX) to Market Perform from Outperform with a price target of $2, down from ...

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendationSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE ...

Explore Syndax Pharmaceuticals' Q4 2024 earnings highlights, including strong Revuforj launch revenue, label expansion plans, and a $2 billion ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch - - Launched Niktimvo (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte - - sNDA ...

Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...